Cryo-Cell International Inc.
CCEL Healthcare Medical Care Facilities
Cryo-Cell International Inc.’s revenue for fiscal 2025 (year ended November 2025) was $31.6 million, down 1.31% from fiscal 2024. In the quarter to August 2026, revenue was flat, EPS grew 77.8%, free cash flow fell 58.4% and total debt fell 29.5%, each against the same quarter a year earlier.
Follow CCEL
Cryo-Cell International Inc. (CCEL) Piotroski F-score
Cryo-Cell International Inc.'s Piotroski F-score for fiscal 2025 is 6 out of 9: 6 of nine tests of profitability, leverage and efficiency passed, down from 9 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 6 | (3.00) |
| FY2024 | 9 | 3.00 |
| FY2023 | 6 | 1.00 |
| FY2022 | 5 | 1.00 |
| FY2021 | 4 | (4.00) |
| FY2020 | 8 | 2.00 |
| FY2019 | 6 | 3.00 |
| FY2018 | 3 | (4.00) |
| FY2017 | 7 | 3.00 |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (3.84%) | 0.64% | Fail | 0 |
| Positive operating cash flow | 5.48m | 6.01m | Pass | 1 |
| Rising return on assets | (3.84%) | 0.64% | Fail | 0 |
| Cash flow above net income | 7.91m | 5.61m | Pass | 1 |
| Falling long-term leverage | 0.13 | 0.13 | Pass | 1 |
| Rising current ratio | 0.59 | 0.58 | Pass | 1 |
| No new shares issued | 8,068,800 | 8,130,700 | Pass | 1 |
| Rising gross margin | 76.63% | 75.15% | Pass | 1 |
| Rising asset turnover | 0.50 | 0.51 | Fail | 0 |
| Piotroski F-score | Mixed | 6 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| JYNT The Joint Corp. compare | 7 |
| BTMD biote Corp. compare | 7 |
| CCM Concord Medical Services Holdings Limited compare | 6 |
| CCEL Cryo-Cell International Inc. | 6 |
| PAIYY Aesthetic Medical International Hldngs Group Ltd Sponsored ADR compare | 5 |
| DCGO DocGo Inc. compare | 3 |
| AIRS AirSculpt Technologies, Inc. compare | 3 |
| PIII P3 Health Partners Inc. compare | 2 |
| PARK Park Dental Partners, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover